Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 7, 1282 - 1284 (2001)
doi:10.1038/nm1201-1282
A new feature on the cholesterol-lowering landscape
Daniel J. Rader1
- Center for Experimental Therapeutics University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA
e-mail: rader@mail.med.upenn.edu
Abstract
Reduction in blood levels of low-density lipoprotein cholesterol reduces the risk of coronary heart disease. The identification of a new class of compounds that upregulate the low-density lipoprotein receptor may lead to new therapeutic advances. (pages 1332–1338)
Increased low-density lipoprotein (LDL) cholesterol is an established risk factor for atherosclerosis, the underlying cause of coronary heart disease (CHD) and most strokes1. The most effective drugs for reducing blood levels of LDL cholesterol are the statins, which have been shown to significantly reduce the risk of coronary events and stroke in clinical trials1.
To read this story in full you will need to login or make a payment (see right).
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE REVIEWS RESEARCH |
